Almac’s North Carolina Facility Continues Growth in Academically based Clinical Trials
News May 05, 2010
The site in Durham which recently doubled capacity and passed an FDA inspection, also operates as a licensed pharmacy. The unit was originally part of the Duke Clinical Research Institute from 1990-2000 with all of the studies handled during this time were physician-led and academically based.
With its academic origins and many of their key Project Leaders fully qualified pharmacists it is not surprising that the site is seeing increased partnerships with academically led Clinical Trials. Staff experienced with this specific client type are aware of the deeper level of involvement required from the outset and have an understanding of the full clinical trial process –disease state knowledge, how patients move through the hospital and pharmacy best practice when working directly with investigators. Project Leaders are also involved with writing the CTM section of the clinical protocol through to reconciling drug returned from the clinical sites at close out.
Donna Christopher, VP of Operations at Almac Clinical Services, Durham Facility commented ‘As our business continues to evolve under the Almac brand we have stayed close to our roots in academically based clinical trials - an area where our expertise lies. Alongside our core contract services, we also advise many of our clients on how to conduct their trials. From the outset we provide information on clinical input, study materials required, efficient drug kits design as well as full supply chain management in addition to providing training and monitoring to sites. We work together with our Academic clients to ensure their clinical trials are run to maximum efficiency enabling them to focus solely on their trial results. . In recent months we have doubled our capacity to enable us to meet the increased demands for our services.”
If you would like more information on the services we provide or are an Academic Institution looking for a partner to manage your clinical trial please visit: http://www.almacgroup.com/clinicalservices/academic-clinical-trials.aspx
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE